Latest News
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
9 October 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Friday that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to its multi-cancer early detection (MCED) assay, su...
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
9 October 2026 - French biopharmaceutical company Medincell S.A. (Euronext Paris: MEDCL) announced on Friday that its partner Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), has received US Food and...
Alumis reports new Phase 3 data showing sustained skin clearance with envudeucitinib
9 October 2026 - US biopharmaceutical company Alumis Inc. (NASDAQ: ALMS) on Friday released new Phase 3 data from its ONWARD1, ONWARD2 and ONWARD3 studies of envudeucitinib in moderate-to-severe plaque psoriasis.Envudeucitinib delivered high-threshol...
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
9 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab ...
Alpheus Medical starts new clinical trial of PoMA therapy in butterfly glioblastoma
9 October 2026 - Clinical-stage biotechnology company Alpheus Medical Inc announced on Thursday the launch of a new clinical trial evaluating its investigational Porphyrin Metabolite Activation (PoMA) therapy in patients with butterfly glioblastoma (...